Elsevier

Oral Oncology

Volume 45, Issue 7, July 2009, Pages 551-554
Oral Oncology

Review
Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update

https://doi.org/10.1016/j.oraloncology.2009.01.002Get rights and content

Summary

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. High potency bisphosphonates are generally implicated and risk factors also include dental extractions. Prevention is of paramount importance. Management is controversial but there is little evidence basis and the consensus is to be conservative. Recent advances in this area are summarised in this concise review.

Introduction

Osteonecrosis of the jaws (ONJ) or bisphosphonate-related osteonecrosis of the jaws (BRONJ) was first reported by Marx (2003).1 This severe complication occurs most frequently in patients on intravenous bisphosphonates treatment for malignant diseases such as multiple myeloma or metastatic malignant disease, mainly breast cancer. Bisphosphonates prevent, reduce and delay cancer-related skeletal complications.2

Many authors however, consider that the benefits of bisphosphonate treatment in malignant disease generally outweigh any risks.3 Some cases of BRONJ have also been reported in patients on oral bisphosphonates treatment for osteoporosis.[4], [5] but millions of patients are on oral bisphosphonates treatment for osteoporosis, and the risk of ONJ is very low indeed6 overall incidence ranging from 1/10,000-1/100,000 treatments,7 and these oral drugs are helpful in preventing hip fractures in older women in particular.

Section snippets

Pathogenesis

Bisphosphonates inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, block osteoclast protein prenylation, and thus block osteoclast-mediated bone resorption.8 This predisposes to BRONJ. There is an inhibition of osteoclast development from monocytes, increased osteoclast apoptosis and prevention of osteoclast development and recruitment from bone marrow precursors.9 Other possible mechanisms include an anti-angiogenic effect and a suppressive effect on endothelial

Incidence

BRONJ is far more frequently induced by intravenous bisphosphonates than by oral bisphosphonates. Hoff et al.13 found that 16 out of 1338 patients with breast cancer (1.2%) and 13 of 548 with myeloma (2.4%) on intravenous bisphosphonate treatment developed BRONJ. Wang et al.14 reported a slightly greater incidence both in myeloma (3.8%), in breast cancer (2.5%) and prostate cancer (2.9%) but Mavrokokki et al.15 reported a lower overall incidence. Recently Stumpe et al.16 found a global

Risk factors

Several studies have focussed on the risk factors for developing BRONJ. Treatment with high potency (nitrogenated) intravenous bisphosphonates such as zoledronic acid and pamidronate, and dental extractions, are important risk factors.[17], [18] The duration of bisphosphonate treatment, the number of infusions and the total infusion hours may also be risk factors for BRONJ.[16], [19]

Other suspected risk factors, which have largely been excluded, include concomitant therapy with corticosteroids,

Prognostication

Marx et al.5 described collagen C-terminal telopeptide (CTX) test as a useful serological marker for the risk of BRONJ, but this has not been supported by other authors.[24], [25] and we found no statistically significant relationship between the serum CTX and the number of exposed bone necrotic areas and the size of BRONJ.26

New clinical forms of presentation

The main clinical signs and symptoms are pain, areas of exposed and necrotic bone with tooth mobility, mucosal swelling, erythema, and ulceration, abscesses and fistulas.12 Ruggiero et al.27 described three stages in BRONJ patients (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6), but some authors have suggested the need to include in this classification early stages where patients without bone exposed may be presented.28 However, Junquera and Gallego29 presented two cases of BRONJ

Diagnostic methods for assessing the extent of lesions

Computed tomography (CT) scan is helpful to assess the size and the extent of bone necrosis30 but magnetic resonance imaging (MRI) is also an effective tool31 though findings are not specific.30

Management

Management of BRONJ remains controversial. The consensus is to manage patients with BRONJ conservatively[7], [32] when at least 23–53% of patients achieve resolution of mucosal discontinuities (Table 1).[13], [33] However, some patients need surgery. Wutzl et al.34 conducting the first prospective study showed that minimal resection of necrotic bone and local soft closure resulted in success in 58.5%. Other authors have reported that surgery can improve the patient’s symptoms and may resolve

Prevention

The importance of preventive measures is thus highlighted.[12], 39, 40 One prospective study found that the risk of BRONJ decreased after the implementation of preventive dental procedures41 and this was supported by another that showed a reduction in BRONJ incidence from 3.2% to 1.3% after a preventive programme.42 Finally, the risk of BRONJ diminishes when the frequency of administration of bisphosphonates is reduced, so a reduced drug schedule may be a useful tool to prevent this severe

Conflict of interest statement

None declared.

References (43)

  • M.E. Sarasquete et al.

    Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

    Blood

    (2008)
  • S. Lehrer et al.

    Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws

    Oral Surg Oral Med Oral Pathol Oral Radiol Endod

    (2008)
  • S. Khosla et al.

    Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment

    J Oral Maxillofac Surg

    (2008)
  • S.L. Ruggiero et al.

    Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management

    Oral Surg Oral Med Oral Pathol Oral Radiol Endod

    (2006)
  • L. Junquera et al.

    Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?

    J Oral Maxillofac Surg

    (2008)
  • S. Bisdas et al.

    Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients

    Clin Radiol

    (2008)
  • L. Montebugnoli et al.

    Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management

    Oral Surg Oral Med Oral Pathol Oral Radiol Endod

    (2007)
  • J.J. Freiberger et al.

    Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series

    J Oral Maxillofac Surg

    (2007)
  • A. Wutzl et al.

    Treatment results of bisphosphonate-related osteonecrosis of the jaws

    Head Neck

    (2008)
  • Novince CM, Ward BB, McCauley LK. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues...
  • S. Khosla et al.

    Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research

    J Bone Miner Res

    (2007)
  • Cited by (73)

    • Adverse events associated with bone-directed therapies in patients with cancer

      2022, Bone
      Citation Excerpt :

      The approximate incidence of MRONJ in cancer patients treated with intravenous bisphosphonates is 1% to 3% [38]. In contrast, the approximate incidence in patients with osteoporosis treated with low-potency oral bisphosphonates or low-dosage denosumab is 0.01 to0.1% [39] [31] [40]. The risk of MRONJ development increases when antiresorptive are used with other concomitant therapies, such as chemotherapeutic agents, antiangiogenic agents, and glucocorticoids [41,42].

    View all citing articles on Scopus
    View full text